Unlike software, a deep-tech hardware startup's first product is essentially a prototype, according to Cerebras CEO Andrew Feldman. The second iteration refines the technology, and only the third generation truly scales and achieves market traction. This necessitates a decade-plus timeline and immense capital before success.

Health tech can't burn cash indefinitely like other tech sectors due to long timelines and complexity. Founders must design their company to achieve profitability at multiple stages, creating self-sustaining platforms before pursuing the next level of growth and investment.

Zipline's journey highlights a mismatch between standard VC fund timelines (10-12 years) and the longer development cycles of "real-world tech" like robotics. Founders in these spaces must be prepared for a 15-20 year journey and communicate this reality to investors from the start.

For bootstrapped startups in industries with long sales cycles and sparse feedback, like healthcare, building speculatively is extremely risky. The safest path is to de-risk development completely by only investing engineering time into features or customizations that a customer has already committed to and paid for.

Gaining FDA approval is not the finish line. Many innovative devices fail because they lack a clear reimbursement strategy. Founders must build the economic case for payers and providers in concert with their clinical and regulatory strategy from day one.

Early-stage MedTech companies often have a limited, narrow understanding of their market size and product-market fit. Their intense focus on product development and regulatory hurdles causes them to neglect crucial commercialization planning, creating a major strategy gap post-approval.

Disruptive MedTech ideas attract investment, but they are high-risk. Founders should de-risk these big bets by developing market access and commercial strategies simultaneously with product development, not after FDA approval.

The path for biotech entrepreneurs is a long slog requiring immense conviction. Success ("liftoff") isn't just a clinical trial result, but achieving self-sustaining profitability and growth. This high bar means founders may need to persevere through years of market indifference and financing challenges.

Even after proving a device works, getting FDA clearance, and securing a reimbursement code, investors' final question is about market traction. They want to see revenue before funding the sales team required to generate it, creating a final catch-22.